Sa502 THE FIRST AND SECOND WAVE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A TEMPORAL TREND ANALYSIS

Abstract Background Cases of coronavirus disease 2019 (COVID-19) have emerged in discrete waves. We explored temporal trends in the reporting of COVID-19 in inflammatory bowel disease (IBD) patients. Methods The Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is an international registry of IBD patients diagnosed with COVID-19. The average percent changes (APCs) were calculated in weekly reported cases of COVID-19 during the periods of March 22 to September 12, September 13 to December 12, 2020, and December 13 to July 31, 2021. Results Across 73 countries, 6404 cases of COVID-19 were reported in IBD patients. COVID-19 reporting decreased globally by 4.2% per week (95% CI, −5.3% to −3.0%) from March 22 to September 12, 2020, then climbed by 10.2% per week (95% CI, 8.1%-12.3%) from September 13 to December 12, 2020, and then declined by 6.3% per week (95% CI, −7.8% to −4.7%). In the fall of 2020, weekly reporting climbed in North America (APC, 11.3%; 95% CI, 8.8-13.8) and Europe (APC, 17.7%; 95% CI, 12.1%-23.5%), whereas reporting was stable in Asia (APC, −8.1%; 95% CI, −15.6-0.1). From December 13, 2020, to July 31, 2021, reporting of COVID-19 in those with IBD declined in North America (APC, −8.5%; 95% CI, −10.2 to −6.7) and Europe (APC, −5.4%; 95% CI, −7.2 to −3.6) and was stable in Latin America (APC, −1.5%; 95% CI, −3.5% to 0.6%). Conclusions Temporal trends in reporting of COVID-19 in those with IBD are consistent with the epidemiological patterns COVID-19 globally.

Download Full-text

P066 Hospitalization and Surgery Rates in Patients With Inflammatory Bowel Disease in Brazil: A Time-Trend Analysis

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000723060.47236.dd ◽

2020 ◽

Vol 115 (1) ◽

pp. S17-S17

Author(s):

Palacio Flávia ◽

Zaltman Cyrla ◽

Heitor de Souza ◽

Moreira Jessica ◽

Luiz Ronir ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Trend Analysis ◽

Bowel Disease ◽

Time Trend ◽

Inflammatory Bowel ◽

Surgery Rates

Download Full-text

Temporal trend in inpatient mortality in inflammatory bowel disease-associated colorectal cancer vs non-inflammatory colorectal cancer: a nationwide retrospective study

International Journal of Colorectal Disease ◽

10.1007/s00384-020-03775-9 ◽

2020 ◽

Author(s):

Estefania Flores ◽

Chimezie Mbachi ◽

Ikechukwu Achebe ◽

Jennifer Asotibe ◽

Emmanuel Palomera-Tejeda ◽

...

Keyword(s):

Colorectal Cancer ◽

Inflammatory Bowel Disease ◽

Retrospective Study ◽

Bowel Disease ◽

Temporal Trend ◽

Inpatient Mortality ◽

Inflammatory Bowel

Download Full-text

P503 Inflammatory bowel disease video-consulting: a satisfaction survey during the second wave of Covid-19 pandemics

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjab076.625 ◽

2021 ◽

Vol 15 (Supplement_1) ◽

pp. S486-S486

Author(s):

A Todeschini

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Clinical Issue ◽

Face To Face ◽

Degree Of Satisfaction ◽

Inflammatory Bowel ◽

High Degree ◽

Second Wave ◽

Substantial Change

Abstract Background During the SARS-CoV-2 pandemic there was a substantial change in providing medical care. National and international statements recommended avoiding face-to-face visit for treatment of patients especially for chronic disease. Also lockdown and social distancing cause a lot of concern among patients, which prefer avoid hospital facilities due to fear of contracting COVID-19. For these reason there was a reorganization of inflammatory bowel disease follow-up visit shifting from traditional visit to telemedicine whereas it’ was possible. Our survey aimed to evaluated satisfaction about follow up video-consulting in IBD patients. Methods From September to December 2020, 75 video-consults were made as follow up in patients with IBD. Video-consult wasn’t performed as first visit nor in patients with new clinical issue. Every consult lasted about 15 minutes. At the end of the visit, a questionnaire of satisfaction was e-mailed to each patient. This questionnaire evaluated several items: satisfaction, difficulty of connection, opportunity to repeat the video-consult even in post-Covid-19 era, safety compared to face-to-face visit, level of concern about Covid-19 disease and fear of in-hospital transmission Results 70% of the patients indicated an high video-consult rating and in most of cases (88%) there were no connection problems. The majority (88%) would like to repeat the tele-visit even in the post-Covid 19 era (77%). Video-consult seemed to be perceived as safer than face-to-face visit even if, in case of urgent consultation, it was preferred a traditional visit. Moreover, Covid-19 infection and fear of in-hospital trasmission was a great concern in the 73% and 58% of the patients respectively. Conclusion In our survey, outpatients reported a very high degree of satisfaction with video consultations. It was an easy and safe tool that may become an integral part of clinical practice in the future.

Download Full-text

A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy

Medicina ◽

10.3390/medicina57101048 ◽

2021 ◽

Vol 57 (10) ◽

pp. 1048

Author(s):

Mirko Di Ruscio ◽

Gianluigi Lunardi ◽

Dora Buonfrate ◽

Federico Gobbi ◽

Giulia Bertoli ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Healthcare Workers ◽

Biological Therapy ◽

Close Contact ◽

Control Group ◽

Exposure Risk ◽

Seroprevalence Study ◽

Inflammatory Bowel ◽

Second Wave

Background and Objectives: Studies have shown a lower prevalence of anti-SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD), including amongst those receiving biological therapy. Aims were to determine the seroprevalence of anti-SARS-CoV-2 antibodies in IBD patients and to assess any association between seropositivity and IBD characteristics. Materials and Methods: Serum from adult IBD patients was prospectively collected between December 2020 and January 2021 and analyzed for anti-SARS-CoV-2 antibodies. Information about IBD characteristics and SARS-CoV-2 exposure risk factors was collected and analyzed. Serum from non-IBD healthcare workers formed the control group. Results: 311 IBD patients on biologics and 75 on mesalazine were enrolled. Ulcerative colitis (UC) extension (p < 0.001), Crohn’s disease (CD) phenotype (p = 0.009) and use of concomitant corticosteroids (p < 0.001) were significantly different between the two IBD groups. Overall seroprevalence among IBD patients was 10.4%. The control group showed a prevalence of 13.0%, not significantly different to that of IBD patients (p = 0.145). Only a close contact with SARS-CoV-2 positive individuals and the use of non-FFP2 masks were independently associated with a higher likelihood of seropositivity amongst IBD patients. Conclusion: In IBD patients, the prevalence of anti-SARS-CoV-2 antibodies is not determined by their ongoing treatment. Disease-related characteristics are not associated with a greater risk of antibody seropositivity.

Download Full-text